AstraZeneca Pharma India, a Bengaluru based pharma MNC, has improved its financial performance during fourth quarter ended March 2015 due to hefty rise in other operating income. The company earned a net profit of Rs.38.13 crore as against a net loss of Rs.2.57 crore in the corresponding quarter of last year. Its net sales improved by 5.8 per cent to Rs.120.80 crore from Rs.114.15 crore.

With improvement in profits, its EPS worked out to positive Rs.15.25 as against negative Rs.1.03 in the last period. Its other operating income related to clinical trials and co-promotion activities increased to Rs.47.75 crore from nil in the same quarter of last year.

For the full year ended March 2015, AstraZeneca's net sales declined by one per cent to Rs.469.05 crore from Rs.473.75 crore in the previous year. Its net loss increased to Rs.20.84 crore from Rs.0.51 crore despite higher other operating income. EPS worked out to negative Rs.8.34 as compared to negative Rs.0.20 in the previous year.